Evidence map›Paper›PMID 19434239›Full record

ArticlePloS one2009

How beta-lactam antibiotics enter bacteria: a dialogue with the porins.

Chloë E James, Kozhinjampara R Mahendran, Alexander Molitor, Jean-Michel Bolla, Andrey N Bessonov, Mathias Winterhalter, Jean-Marie Pagès

Abstract read
In one paragraph

Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Whole genome sequencing and genotypingAccess microbiology · 2024
    Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Antibiofilm and Antimicrobial-Enhancing Activity ofPathogens (Basel, Switzerland) · 2021
    Article
  15. Differential Expression ofMolecules (Basel, Switzerland) · 2021
    Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Clinical microbiology reviews · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chloë E JamesUMR-MD-1, Transporteurs membranaires, Chimiorésistance et Drug Design, Faculté de Médecine, IFR 88, Université de la Méditerranée, Marseille, France.
Kozhinjampara R Mahendran
Alexander Molitor
Jean-Michel Bolla
Andrey N Bessonov
Mathias Winterhalter
Jean-Marie Pagès

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMulti-drug resistant (MDR) infections have become a major concern in hospitals worldwide. This study investigates membrane translocation, which is the first step required for drug action on internal bacterial targets. beta-lactams, a major antibiotic class, use porins to pass through the outer membrane barrier of Gram-negative bacteria. Clinical reports have linked the MDR phenotype to altered membrane permeability including porin modification and efflux pump expression. METHODOLOGY/PRINCIPAL

findingsHere influx of beta-lactams through the major Enterobacter aerogenes porin Omp36 is characterized. Conductance measurements through a single Omp36 trimer reconstituted into a planar lipid bilayer allowed us to count the passage of single beta-lactam molecules. Statistical analysis of each transport event yielded the kinetic parameters of antibiotic travel through Omp36 and distinguishable translocation properties of beta-lactams were quantified for ertapenem and cefepime. Expression of Omp36 in an otherwise porin-null bacterial strain is shown to confer increases in the killing rate of these antibiotics and in the corresponding bacterial susceptibility. CONCLUSIONS/SIGNIFICANCE: We propose the idea of a molecular "passport" that allows rapid transport of substrates through porins. Deciphering antibiotic translocation provides new insights for the design of novel drugs that may be highly effective at passing through the porin constriction zone. Such data may hold the key for the next generation of antibiotics capable of rapid intracellular accumulation to circumvent the further development MDR infections.

Indexed as

Anti-Bacterial Agentsbeta-LactamsBiological TransportEscherichia coliEscherichia coli ProteinsKineticsLipid BilayersPorinsAnti-Bacterial Agentsbeta-LactamsEscherichia coli ProteinsLipid BilayersPorins

Identifiers

PMID19434239
PMCPMC2677626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.